Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yun Fan

Showing results (891-900 of 920) with videos related to

Pageof 92
Sort By:
The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.
Therapeutic Advances in Medical Oncology|July 24, 2023
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populationsJun Wang, Bicheng Zhang, Ling Peng, et al.
Med (New York, N.Y.)|October 10, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trialQing Zhou, Yan Yu, Ligang Xing, et al.
ERJ Open Research|February 27, 2024
A phase 4 multicentre, 2×2 factorial randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of tobramycin inhalation solution for <i>Pseudomonas aeruginosa</i> eradication in bronchiectasis: ERASEYong-Hua Gao, Hai-Wen Lu, Hui-Zhen Zheng, et al.
Nature Communications|July 3, 2021
Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinomaYun-Fan Sun, Liang Wu, Shi-Ping Liu, et al.
The Lancet. Respiratory Medicine|January 13, 2025
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort studyJin-Fu Xu, Hui-Zhen Zheng, Hai-Wen Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA SequencingYunpeng Yang, Jie Huang, Tao Wang, et al.
Cancer Communications (London, England)|February 29, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II studyJing Zheng, Tao Wang, Yunpeng Yang, et al.
Theranostics|January 4, 2021
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinomaTao Jiang, Liyan Jiang, Xiaorong Dong, et al.
The Lancet. Respiratory Medicine|May 27, 2023
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 studyShun Lu, Jianying Zhou, Hong Jian, et al.
Pageof 92

Showing results (891-900 of 920) with videos related to

Sort By:
Pageof 92
The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.
Therapeutic Advances in Medical Oncology|July 24, 2023
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populationsJun Wang, Bicheng Zhang, Ling Peng, et al.
Med (New York, N.Y.)|October 10, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trialQing Zhou, Yan Yu, Ligang Xing, et al.
ERJ Open Research|February 27, 2024
A phase 4 multicentre, 2×2 factorial randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of tobramycin inhalation solution for <i>Pseudomonas aeruginosa</i> eradication in bronchiectasis: ERASEYong-Hua Gao, Hai-Wen Lu, Hui-Zhen Zheng, et al.
Nature Communications|July 3, 2021
Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinomaYun-Fan Sun, Liang Wu, Shi-Ping Liu, et al.
The Lancet. Respiratory Medicine|January 13, 2025
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort studyJin-Fu Xu, Hui-Zhen Zheng, Hai-Wen Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA SequencingYunpeng Yang, Jie Huang, Tao Wang, et al.
Cancer Communications (London, England)|February 29, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II studyJing Zheng, Tao Wang, Yunpeng Yang, et al.
Theranostics|January 4, 2021
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinomaTao Jiang, Liyan Jiang, Xiaorong Dong, et al.
The Lancet. Respiratory Medicine|May 27, 2023
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 studyShun Lu, Jianying Zhou, Hong Jian, et al.
Pageof 92